MAP3K7 and prostate cancer: To thoroughly evaluate the heterogeneity for MAP3K7 deletions and TMPRSS2:ERG fusion status and their interrelationship in prostate cancer, we took advantage of a newly developed heterogeneity tissue microarray (TMA) containing samples from 10 different tumor blocks of 189 large prostate cancers.